MD4546B1 - Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron - Google Patents

Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron

Info

Publication number
MD4546B1
MD4546B1 MDA20150054A MD20150054A MD4546B1 MD 4546 B1 MD4546 B1 MD 4546B1 MD A20150054 A MDA20150054 A MD A20150054A MD 20150054 A MD20150054 A MD 20150054A MD 4546 B1 MD4546 B1 MD 4546B1
Authority
MD
Moldova
Prior art keywords
product including
receptor modulator
progesterone receptor
selective progesterone
including selective
Prior art date
Application number
MDA20150054A
Other languages
English (en)
Russian (ru)
Other versions
MD4546C1 (ro
MD4546B9 (ro
MD20150054A2 (ro
Inventor
Флориан Баттюн
Пьер-Ив Жувен
Жером Эк
Оде Колен
Original Assignee
Laboratoire Hra-Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Hra-Pharma filed Critical Laboratoire Hra-Pharma
Publication of MD20150054A2 publication Critical patent/MD20150054A2/ro
Publication of MD4546B1 publication Critical patent/MD4546B1/ro
Publication of MD4546B9 publication Critical patent/MD4546B9/ro
Publication of MD4546C1 publication Critical patent/MD4546C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)

Abstract

Invenţia se referă la un produs de comicronizare ce cuprinde un ingredient activ selectat din grupul format din modulatori selectivi ai receptorului de progesteron, metaboliţi ai acestora şi amestecuri de metaboliţi, şi un excipient polimeric în bază de N-vinil-2-pirolidonă.Invenţia de asemenea se referă la un procedeu de obţinere a produsului de comicronizare şi la o compoziţie farmaceutică ce conţine produsul de comicronizare menţionat.
MDA20150054A 2012-11-08 2013-11-07 Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron MD4546C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1260605A FR2997628B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
PCT/FR2013/052671 WO2014072647A1 (fr) 2012-11-08 2013-11-07 Produit de co-micronisation comprenant un modulateur selectif du recepteur a la progesterone

Publications (4)

Publication Number Publication Date
MD20150054A2 MD20150054A2 (ro) 2015-10-31
MD4546B1 true MD4546B1 (ro) 2018-01-31
MD4546B9 MD4546B9 (ro) 2018-08-31
MD4546C1 MD4546C1 (ro) 2019-03-31

Family

ID=47714259

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150054A MD4546C1 (ro) 2012-11-08 2013-11-07 Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron

Country Status (22)

Country Link
US (1) US20150258118A1 (ro)
EP (1) EP2916823B1 (ro)
JP (1) JP2015536969A (ro)
CN (1) CN105073098B (ro)
CR (1) CR20150298A (ro)
CY (1) CY1118884T1 (ro)
DK (1) DK2916823T3 (ro)
EA (1) EA029643B1 (ro)
EC (1) ECSP15022505A (ro)
ES (1) ES2625012T3 (ro)
FR (1) FR2997628B1 (ro)
GE (1) GEP201706648B (ro)
HR (1) HRP20170686T1 (ro)
LT (1) LT2916823T (ro)
MD (1) MD4546C1 (ro)
PL (1) PL2916823T3 (ro)
PT (1) PT2916823T (ro)
RS (1) RS55956B1 (ro)
SI (1) SI2916823T1 (ro)
SM (1) SMT201700237T1 (ro)
UA (1) UA115573C2 (ro)
WO (1) WO2014072647A1 (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) * 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0422100A1 (en) * 1988-06-23 1991-04-17 Res Triangle Inst SUBSTITUTED PROGESTERONE ANALOGS 11-g (b).
EP0803250A1 (en) * 1996-04-24 1997-10-29 American Home Food Products, Inc. Controlled release of steroids from sugar coatings
EP1602662A1 (en) * 2003-01-22 2005-12-07 Crystal Pharma, S.A. Method of obtaining 17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
WO2008067086A2 (en) * 2006-10-24 2008-06-05 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
WO2009134723A1 (en) * 2008-04-28 2009-11-05 Repros Therapeutics Inc. Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer
US20100144692A1 (en) * 2008-12-08 2010-06-10 Laboratoire Hra Pharma Ulipristal Acetate Tablets
CN102871977A (zh) * 2012-10-19 2013-01-16 北京紫竹药业有限公司 醋酸优力司特分散片及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
AU2005265357B2 (en) 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
EA200970646A1 (ru) * 2006-12-28 2009-12-30 Репрос Терапьютикс Инк. Способы и составы для улучшения биодоступности антипрогестинов
JP2008169135A (ja) * 2007-01-11 2008-07-24 Takada Seiyaku Kk グリメピリド組成物の製造方法
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
HRP20161437T1 (hr) 2009-04-14 2017-02-10 Laboratoire Hra Pharma Postupak hitne kontracepcije
WO2011059074A1 (ja) * 2009-11-13 2011-05-19 森六ケミカルズ株式会社 微粉末の製造方法および同方法で製造された微粉末
FR2988610B1 (fr) * 2012-03-30 2014-10-31 Effik Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0422100A1 (en) * 1988-06-23 1991-04-17 Res Triangle Inst SUBSTITUTED PROGESTERONE ANALOGS 11-g (b).
EP0803250A1 (en) * 1996-04-24 1997-10-29 American Home Food Products, Inc. Controlled release of steroids from sugar coatings
EP1602662A1 (en) * 2003-01-22 2005-12-07 Crystal Pharma, S.A. Method of obtaining 17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
WO2008067086A2 (en) * 2006-10-24 2008-06-05 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
WO2009134723A1 (en) * 2008-04-28 2009-11-05 Repros Therapeutics Inc. Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer
US20100144692A1 (en) * 2008-12-08 2010-06-10 Laboratoire Hra Pharma Ulipristal Acetate Tablets
WO2010066749A2 (en) * 2008-12-08 2010-06-17 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102871977A (zh) * 2012-10-19 2013-01-16 北京紫竹药业有限公司 醋酸优力司特分散片及其制备方法

Also Published As

Publication number Publication date
CN105073098A (zh) 2015-11-18
CR20150298A (es) 2015-08-14
JP2015536969A (ja) 2015-12-24
ES2625012T3 (es) 2017-07-18
CN105073098B (zh) 2019-02-19
UA115573C2 (uk) 2017-11-27
FR2997628A1 (fr) 2014-05-09
HRP20170686T1 (hr) 2017-09-08
EA029643B1 (ru) 2018-04-30
MD4546C1 (ro) 2019-03-31
ECSP15022505A (es) 2016-01-29
SMT201700237T1 (it) 2017-07-18
EA201500514A1 (ru) 2015-09-30
WO2014072647A1 (fr) 2014-05-15
EP2916823B1 (fr) 2017-02-15
LT2916823T (lt) 2017-07-25
EP2916823A1 (fr) 2015-09-16
US20150258118A1 (en) 2015-09-17
DK2916823T3 (en) 2017-05-15
GEP201706648B (en) 2017-03-27
FR2997628B1 (fr) 2015-01-16
MD4546B9 (ro) 2018-08-31
MD20150054A2 (ro) 2015-10-31
CY1118884T1 (el) 2018-01-10
SI2916823T1 (sl) 2017-08-31
PL2916823T3 (pl) 2017-08-31
RS55956B1 (sr) 2017-09-29
PT2916823T (pt) 2017-05-22

Similar Documents

Publication Publication Date Title
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
WO2012037411A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
MD4591B1 (ro) Dispersie solidă a unui modulator selectiv al receptorului de progesteron
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
EP2978420A4 (en) STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MD20150054A2 (ro) Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron
EA201400444A1 (ru) Производные 2-оксопиперидинила
EP2875814A4 (en) LIQUID COMPOSITION CONTAINING TAXANE ACTIVE INGREDIENT, MANUFACTURING METHOD THEREOF, AND LIQUID MEDICINAL PREPARATION
WO2015095659A3 (en) Indirubin solid dispersion composition
PH12014502325A1 (en) Sustained release tablet containing levodropropizine and method for preparing same
CA2865252A1 (en) Sulfinylbenzyl and thiobenzyl derivatives as sphingosine 1-phosphate (s1p) receptor modulators
WO2013067105A3 (en) Nicotinic receptor non-competitive modulators
HK1189891A1 (zh) 作为趋化因子受体调节剂的硫衍生物
HK1223088A1 (zh) 阿戈美拉汀和磺酸的新复合物、其制备方法和包含其的药物组合物

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees